More toxic drugs may limit their use in vivo and improve in vivo safety by developing a novel drug, α-amanitin-conjugated trastuzumab, which kills tumor cells while inducing immunogenic cell death, using the HER2 antibody trastuzumab coupled to α-amanitin, and cells containing 17p deletion, which are expressed at low levels of HER2 (Li et al., 2021). The gene discussed is ERBB2; the disease is neoplasm.